A Study of MZE782 in Adults With PKU
ConditionPhenylketonuria (PKU)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMaze Therapeutics
About this trial
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).
Eligibility criteria
Qualifiers
Males and females 18 to 75 years old
Clinical diagnosis of PKU
Willing and able to keep diet and protein intake consistent during the study
For some study groups, is willing and able to stop certain PKU medications before starting study treatment
Disqualifiers
Is pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study or within 90 days after the last dose
Medical conditions or abnormal test results that could make participation unsafe or make it difficult to complete study procedures or interpret study results
Has recently received another investigational drug
Is unable to swallow tablets or tolerate oral medication
Trial design
Treatments tested in this trial
- MZE782
- Placebo
- MZE782
Treatment groups
38 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov